Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.

JCI insight - 6 Aug 2020

Nokin Marie-Julie, Darbo Elodie, Travert Camille, Drogat Benjamin, Lacouture Aurélie, San José Sonia, Cabrera Nuria, Turcq Béatrice, Prouzet-Mauleon Valérie, Falcone Mattia, Villanueva Alberto, Wang Haiyun, Herfs Michael, Mosteiro Miguel, Jänne Pasi A, Pujol Jean-Louis, Maraver Antonio, Barbacid Mariano, Nadal Ernest, Santamaría David, Ambrogio Chiara

Abstract excerpt

Platinum-based chemotherapy in combination with immune-checkpoint inhibitors is the current standard of care for patients with advanced lung adenocarcinoma (LUAD). However, tumor progression evolves in most cases. Therefore, predictive biomarkers are needed for better patient stratification and for the identification of new therapeutic strategies, including enhancing the efficacy of chemotoxic agents. Here, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Movement

Share to Cisplatin

Share to Drug Resistance, Neoplasm

Share to Paclitaxel

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32759499
DOI: 10.1172/jci.insight.137869
PMCID: PMC7455065

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.PMID 32759499Read ↗

Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.Semantic proximity Read ↗

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.Semantic proximity Read ↗

Discoidin domain receptor 1 as a potent therapeutic target in solid tumorsSemantic proximity Read ↗

Targeting DNA Damage Response-Mediated Resistance in Non-Small Cell Lung Cancer: From Mechanistic Insights to Drug DevelopmentSemantic proximity Read ↗

A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance.Semantic proximity Read ↗

RDM1 plays an oncogenic role in human lung adenocarcinoma cellsSemantic proximity Read ↗

Inhibition of DKC1 induces telomere-related senescence and apoptosis in lung adenocarcinomaSemantic proximity Read ↗

CUL4B functions as a tumor suppressor in KRAS-driven lung tumors by inhibiting the recruitment of myeloid-derived suppressor cells.Semantic proximity Read ↗

DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell linesSemantic proximity Read ↗

DEPDC1 up‐regulates RAS expression to inhibit autophagy in lung adenocarcinoma cellsSemantic proximity Read ↗

Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients.Semantic proximity Read ↗

Inhibitor of Differentiation-1 Sustains Mutant KRAS -Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 NetworkSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.